Bristol’s Goal: 2 New Biologics/Year In Clinic – R&D Chief
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb’s R&D team plans to boost discovery output by 50 percent with only a modest increase in spending over three years, exec says.
You may also be interested in...
Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.
Bristol-Myers Squibb Eyes A Jewel To Add To Its String Of Pearls
$4.5 billion cash takeover of ImClone would give BMS 100 percent of North American Erbitux sales that totaled $700 million in the first half.
BMS Licenses Kai Heart Drug For $227 Million
Delta protein kinase C inhibitor was given up by Daiichi Sankyo in 2007.